AXSM vs EXEL
Axsome Therapeutics, Inc. and Exelixis, Inc., both Healthcare
Exelixis, Inc. is the larger company at $13B against $12B. Over the past year EXEL returned +49% against +45% for AXSM. The RyuScore puts EXEL ahead, 80 against 18 out of 100.
| Figure | AXSM | EXEL |
|---|---|---|
| Last close | $168 | $59.86 |
| Market cap | $12B | $13B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 18.8 |
| 1-year return | +45% | +49% |
| 5-year return | +544% | +197% |
| RyuScoresector-relative, 1–10 | 18/100 | 80/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Axsome Therapeutics, Inc.
Revenue of $218M in Q2 2026, net income null. Its largest reported line is Royalty And Milestone, 66% of the disclosed total.
Exelixis, Inc.
Revenue of $629M in Q2 2026, net income $212M. Its largest reported line is Product Gross, 87% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.